Monash-led Pcos Renamed to Polyendocrine Metabolic Ovarian Syndrome
Polycystic ovary syndrome has been pcos renamed Polyendocrine Metabolic Ovarian Syndrome after a 14-year global collaboration led by Helena Teede. The change is designed to better reflect the condition that affects more than 170 million women worldwide and to support diagnosis, care, awareness and understanding.
The new name will be fully implemented in the 2028 International Guideline update. A three-year transition period will be backed by a major international education and awareness campaign, giving clinicians and patients time to adjust to the revised terminology.
Helena Teede and Monash
Teede, director of Monash University’s Monash Centre for Health Research & Implementation and an endocrinologist at Monash Health, led the name change process. She called it a landmark moment and said, “What we now know is that there is actually no increase in abnormal cysts on the ovary, and the diverse features of the condition were often unappreciated.”
She also said, “While international guidelines have advanced awareness and care, a name change was the next critical step towards recognition and improvement in the long-term impacts of this condition.” The old name, polycystic ovary syndrome, had focused attention on ovaries and cysts, while the condition is described as affecting hormones, weight, metabolic and mental health, skin and the reproductive system.
Patient groups and survey responses
The process drew in more than 50 patient and professional organizations, along with multiple international workshops involving patients and multidisciplinary health professionals. It also produced more than 22,000 survey responses, part of a patient-focused effort that shaped the final wording.
Teede said, “The agreed principles of the new name included patient benefit, scientific accuracy, ease of communication, avoidance of stigma, cultural appropriateness and accompanying implementation,” and added, “This change was driven with and for those affected by the condition and we are proud to have arrived at a new name that finally accurately reflects the complexity of the condition.”
2028 International Guideline
The renamed condition carries a practical shift for readers who have lived with a PCOS diagnosis: medical materials, awareness campaigns and guideline language are being aligned around the new term over the three-year transition. Teede said, “Make no mistake, this is a landmark moment that will lead to desperately needed worldwide advancements in clinical practice and research.”
The rename does not change the number of people affected. The condition still impacts 1 in 8 women worldwide, and the 2028 International Guideline update is the point at which the new name will be fully in place.
